louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01537445: MR-Evaluation of Renal Function-After-Pancreas-transplantation
Official title: MR-Evaluation of Renal Function-After-Pancreas-transplantation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diabetes
Renal Failure
Pancreas Transplantation
Keywords: Diabetes Mellitus
Pancreas
Renal failure
Transplantation
Lead sponsor: Uppsala University
Sponsor class: OTHER
First posted: 2012-02-23
Enrollment: 40
Sex: ALL
Minimum age (years): 15
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with diabetes mellitus

Brief summary: The purpose of this study is to evaluate the beneficial effect of pancreas transplantation for long term kidney function in patients undergoing single-pancreas transplantation.

Detailed description: Renal failure in patients who have performed a pancreas transplantation is a hazard for the outcome for these patients. The beneficial effect of pancreas transplantation for renal function is not clear. It is of major importance to early find patients who develops a decrease in renal function and start treatment early and closely monitor these patients in order to avoid further deteriorating renal function. In order to achieve this, there is a need for a easy, fast and sensitive method to evaluate renal function. In this study the investigators plan to use the non-invasive MR to evaluate changes in renal function.

Eligibility criteria: Inclusion Criteria:

* Patients with diabetes mellitus
* Patients undergoing a pancreas transplantation

Exclusion Criteria:

* Patients undergoing a pancreas transplantation and a renal transplantation at the same time.

Primary outcomes:
measure: Kidney function
timeFrame: Within 3 years
Secondary outcomes:
measure: Kidney hemodynamics and oxygenation
timeFrame: Within 3 years
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: University Hospital
Study officials:
affiliation: Uppsala University, Uppsala, Sweden
name: Per Liss, MD, PhD.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06444945: Effects of Mulligan Mobilization With Movement as Compared to Kaltenborn Joint Mobilization in the Management of Knee Osteoarthritis
Official title: Effects of Mulligan Mobilization With Movement as Compared to Kaltenborn Joint Mobilization in the Management of Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Knee Osteoarthritis
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-06-06
Enrollment: 40
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel designed randomized control trial
Primary purpose: TREATMENT

Brief summary: This study is a randomised controlled trial and the purpose of this study is to determine the Effects of Mulligan mobilization with movement as compared to Kaltenborn joint mobilization in the management of knee osteoarthritis." To determine the effects of Mulligan MWM as compared to Kaltenborn joint mobilization in terms of pain, function, range of motion and gait in persons with knee osteoarthritis.


Eligibility criteria: Inclusion Criteria:

* Individuals aged 40-70 years (Osama et al, 2022)
* Having KOA history of no less than 3 months
* Knee pain less than 8/10 on numeric pain rating scale (NPRS).
* Radiological evidence of grade III or less on Kellgren classification
* Patients referred from rehab department

Exclusion Criteria:

* Those with signs of serious pathology, such as malignancy, inflammatory disorder or infection.
* History of trauma or fractures in lower extremity.
* Signs of lumbar radiculopathy or myelopathy.
* History of knee surgery or replacement.
* Receiving intra-articular steroid therapy in the preceding two months.

Primary outcomes:
measure: knee pain
timeFrame: 2 weeks
measure: Functional disability
timeFrame: 2 weeks
measure: Knee range of motion
timeFrame: 2 weeks
measure: Stride length
timeFrame: 2 weeks
measure: Gait velocity
timeFrame: 2 weeks
measure: Isometeric Muscle Strength
timeFrame: 2 weeks
measure: Walking related performance fatigability
timeFrame: 2 weeks
measure: Functional Capacity
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University Islamabad
Study officials:
affiliation: Foundation University Islamabad
name: Shanza Fatima, DPT
role: PRINCIPAL_INVESTIGATOR
affiliation: Foundation University Islamabad
name: Muhammad Osama, PHD*
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07002645: The Effect of Web-Based Conflict Resolution Training Applied to Intensive Care Nurses
Official title: The Effect of Web-Based Conflict Resolution Training Applied to Intensive Care Nurses on the Conflict Resolution Skills of Nurses
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Conflict Resolution, Intensive Care Nurses, Web-based Training
Keywords: conflict resolution, intensive care nurses, web-based training
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2025-06-03
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will be conducted in a randomized parallel controlled experimental study design to determine the effect of web-based conflict resolution training to be applied to intensive care nurses on the conflict resolution skills of nurses.

The study will be conducted with 46 nurse (23 intervention, 23 control groups) working in the Intensive Care Units of an University Hospital between May 2025 and September 2026.

Web-based conflict resolution training program will be applied to the intervention group for 2 week.No application will be made to the control group. The data collection tools in the study are the Identifier Information Form, Conflict Resolution Scale, and Satisfaction Survey for Web-Based Conflict Resolution Training.


Eligibility criteria: Inclusion Criteria:

* Being 18 years of age or older
* Having worked in intensive care for at least six months
* Having access to the internet
* Able to use the internet
* Agree to participate in the study

Exclusion Criteria:

* Having a high school or associate degree,
* Having been temporarily assigned to an intensive care unit.
* Leaving the research voluntarily,
* Not completing the training sessions,
* Not participating in the activities in the Training Modules.

Primary outcomes:
measure: Conflict Resolution Scale
timeFrame: The Conflict Resolution Scale will be applied for pretest. The Conflict Resolution Scale will be reapplied after two week the pretest.
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University
state: Çankaya
Study officials:
References:
Clinical trial NCT00154245: A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Transplantation
Keywords: Enteric-coated mycophenolate sodium, transplantation, de novo, cyclosporine
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-09-12
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The study is a one-year prospective, open-label, safety and efficacy study. De novo renal transplant recipients will be receiving cyclosporine, 1.44g EC-MPS (720 mg b.i.d.), and corticosteroids .The study will consist of a 12-month open-label treatment period on EC-MPS.


Eligibility criteria: Inclusion Criteria:

Males and females aged 18-75 years. Recipients of de novo cadaveric, living unrelated or living related kidney transplants

Exclusion Criteria:

Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any organ.

Patients who are recipients of A-B-O incompatible transplants. Patients with a historical or current peak PRA of 50%. Patients with already existing antibodies against the HLA-type of the receiving transplant.

Evidence of severe liver disease (incl. abnormal liver profile i.e. AST, ALT or total bilirubin 3 times UNL).

Patients who are HIV or Hepatitis B surface antigen positive. Patients with any known hypersensitivity to mycophenolic acid, MMF, EC-MPS, other components of the formulation (e.g. lactose).

Patients with thrombocytopenia (75,000/mm3), with an absolute neutrophil count of \< 1,500/mm3, and/or leukocytopenia (\< 2,500/mm3), and/or hemoglobin \< 6 g/dL at Screening or Baseline.

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Graft function 6 months post transplantation
Secondary outcomes:
measure: Incidence of biopsy proven acute rejection, graft loss or death within 6 and 12 months post transplantation
measure: Incidence of biopsy proven acute rejection within 6 and 12 months post transplantation
measure: Time to first biopsy-proven acute rejection
measure: Severity of biopsy-proven acute rejection
measure: Graft survival and patient survival at 6 and 12 months
Other outcomes:
Locations:
Study officials:
affiliation: Novartis
name: Novartis
role: STUDY_DIRECTOR
References:
Clinical trial NCT00358345: PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
Official title: PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Age Related Macular Degeneration
Keywords: AMD
Lead sponsor: Notal Vision Inc.
Sponsor class: INDUSTRY
First posted: 2006-07-31
Enrollment: 347
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: At least 200 subjects with intermediate AMD in at least one (1) eye based on medical record review and/or clinical diagnosis and at least 200 subjects with neovascular AMD in at least one (1) eye.

Brief summary: The primary objective of this study is to assess the ability of the PreView PHP(study device)to detect newly diagnosed non-treated Choroidal Neovascularization (CNV)lesion associate with advanced Age-related Macular Degeneration (AMD) or Myopia and differentiate them from Intermediate AMD or Geographic Atrophy (GA)or patients with high Myopia with no CNV.

This study secondary is to enhance NotalVision normative database.

Detailed description: * The study is prospective, multi-center, comparative study.
* A clinical trail with FDA approval device (510K).

Eligibility criteria: Inclusion Criteria:

* Newly diagnosed (up yo 2 months) CNV OR Intermediate AMD
* Age \>50 for AMD subjects
* Age \>18 for Myopic subjects
* VA 20/160 or better in the study eye
* Mental and physical ability to performed a PHP test

Exclusion Criteria:

* Evidence of macular disease other than AMD or high myopia in the study eye.
* Previous surgical or laser treatment within the macular erea.
* Concurrent intraocular drug therapy (within 30 days).
* Present of any significant media opacity that preclude a clear veiw of the macula.
* Any non macular related ocular surgery performed within 3 months prior to the study.
* CNV subjects inability to tolerate intravenous fluorscien angiography.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky medical center
Study officials:
affiliation: Notal Vision
name: Ofer Sharon, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04151745: Effect of Atrial Pacing on Right Ventricular Function After Cardiac Surgery
Official title: Effect of Atrial Pacing on Right Ventricular Function After Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Right Ventricular Ejection Fraction
Lead sponsor: Frisius Medisch Centrum
Sponsor class: OTHER
First posted: 2019-11-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: To investigate the effects of atrial pacing on right ventricular function and hemodynamics after open heart surgery.
Primary purpose: DIAGNOSTIC

Brief summary: Temporary pacing with an external pacemaker after open heart surgery - besides preventing arrhythmias and AV-conduction disorders - is used to improve cardiac output. In theory, postoperative stunning temporarily limits stroke volume and SA-node dysfunction compromises an adequate compensatory rise in heartrate to ensure sufficient cardiac output. There is a lack of consensus regarding the use of this form of pacing. Protocols vary widely between hospitals. Moreover, the scientific base for this form of pacing mainly comprises studies dating back to the nineteen sixties and seventies. Major changes in (operating) techniques have taken place since then. Also, the role of the right ventricle in this context has not been studied specifically. The current study aims to investigate the effects of atrial pacing on right ventricular function specifically and hemodynamics in general, in today's postoperative setting. We hypothesize that a reduction in heart rate may lead to decreased right ventricular function.

Detailed description: When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning. No additional hemodynamic interventions will be allowed in these periods.

Eligibility criteria: Inclusion Criteria:

* age 18 years or older
* admitted to the ICU after onpump open heart surgery
* Swan Ganz thermodilurion catheter in situ

Exclusion Criteria:

* participation other trials
* off pump cardiac surgery

Primary outcomes:
measure: right ventricular ejection fraction
timeFrame: 30 minutes after procedure
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Intensive Care
name: E C Boerma, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00124345: Medical Gas Humidification During Noninvasive Mechanical Ventilation
Official title: The Humidification During Noninvasive Mechanical Ventilation Delivered by Helmet
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiration, Artificial
Critical Illness
Keywords: temperature
humidity
non invasive mechanical ventilation
Lead sponsor: Policlinico Hospital
Sponsor class: OTHER
First posted: 2005-07-27
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study, the investigators aimed to study the role of medical gas humidification during noninvasive mechanical ventilation.

Detailed description: The medical gases are usually dry and cold thus when they are used during invasive mechanical ventilation they must be conditioned. No data are present on the necessity to condition the medical gases during non invasive mechanical ventilation. In this study the investigators studied the humidity and the temperature of the medical gases with and without any conditioning during non invasive mechanical ventilation in a group of healthy subjects and critically ill patients.

Eligibility criteria: Inclusion Criteria:

* Critically ill patients requiring non invasive mechanical ventilation

Exclusion Criteria:

* Comatose patients

Primary outcomes:
measure: The level of temperature and humidity
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Policlinico Hospital
Study officials:
affiliation: Policlinico Hospital
name: Davide Chiumello, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03193645: Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix
Official title: Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Lead sponsor: Ferring Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2017-06-21
Enrollment: 150
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients will be enrolled by urologists in private clinics or hospital clinics.

Brief summary: The DUO study's main objective is to evaluate, in the real life, the prevalence of cardiovascular risk in patients with prostate cancer that hormone treatment of androgen suppression by Degarelix was introduced.

This study will also assess, at the initiation of therapy, the prevalence of osteoporosis, metabolic comorbidities, depression, sexual and geriatric patients suffering from prostate cancer.


Eligibility criteria: Inclusion Criteria:

* Male aged 18 years or older
* Diagnosed with prostate cancer
* Patient having received an antagonist of GnRH Degarelix prescription.
* Agreeing to and capable of completing in French during the visits all questionnaires on the impact of their illness and treatment.
* Patients having received oral and written study information, agreeing to the use of his anonymized data, and having signed a written Informed Consent Form.

Exclusion Criteria:

* Patient included in an interventional study assessing treatment for prostate cancer.
* Patient presenting hypersensitivity to Degarelix or one of its excipients.
* Patient treated by other hormonotherapy.

Primary outcomes:
measure: Occurrence of cardiovascular comorbidity
timeFrame: At inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Orléans
country: France
facility: Hopital de la Source (there may be multiple sites in this country)
Study officials:
affiliation: Ferring Pharmaceuticals
name: Global Clinical Compliance
role: STUDY_DIRECTOR
References:
Clinical trial NCT01680445: Telephone Interview Study for Men and Women With Osteoarthritis
Official title: Observational Telephone Interview Study for Men and Women With Osteoarthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoarthritis
Keywords: osteoarthritis, arthritis
Lead sponsor: Health Outcomes Solutions
Sponsor class: OTHER
First posted: 2012-09-07
Enrollment: 23
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: US residents

Brief summary: The telephone interviews will be conducted to gather information on goal setting and goal attainment from men and women with osteoarthritis.

Detailed description: Interview data used to develop a new self-administered questionnaire

Eligibility criteria: Inclusion Criteria:

* Between 40 and 80 years of age
* Have moderate to severe pain
* Diagnosed with osteoarthritis of the hip and/or knee at least 6 months ago
* Currently receiving treatment for osteoarthritis
* Able to speak and read English
* US resident
* Willing to share your thoughts and experiences in a 45-minute telephone interview

Exclusion Criteria:

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Winter Park
country: United States
facility: Health Outcomes Solutions
state: Florida
Study officials:
affiliation: Health Outcomes Solutions
name: Susan Mathias
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05858645: Correction of Psoriatic T Cell Signatures by Deucravacitinib
Official title: Correction of Psoriatic T Cell Signatures by Deucravacitinib
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Psoriasis Vulgaris
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
First posted: 2023-05-15
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Detailed description: This is a one-arm, open-label study to examine the effect of deucravacitinib on cutaneous and blood immune cells of psoriatic patients. 25 subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for deucravacitinib-corrected signatures.

Eligibility criteria: Inclusion Criteria:

1. 18 years of age or older
2. Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)

Exclusion Criteria:

1. taking systemic immunosuppressives in the last 12 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Primary outcomes:
measure: Change in Psoriasis Area and Severity Index (PASI) score
timeFrame: pre-treatment, 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
Study officials:
affiliation: University of California, San Francisco
name: Raymond Cho, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: